Cardiac Arrhythmias Therapeutics

Cardiac Arrhythmias Therapeutics


Global Cardiac Arrhythmias Therapeutics Market to Reach US$5.8 Billion by 2030

The global market for Cardiac Arrhythmias Therapeutics estimated at US$4.8 Billion in the year 2023, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Sodium-Channel Blockers, one of the segments analyzed in the report, is expected to record a 2.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Beta-Blockers segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 5.4% CAGR

The Cardiac Arrhythmias Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.2 Billion by the year 2030 trailing a CAGR of 5.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Cardiac Arrhythmias Therapeutics Market - Key Trends and Drivers Summarized

Cardiac arrhythmias therapeutics encompass a broad range of treatments aimed at managing and correcting irregular heartbeats, which can vary from benign to life-threatening conditions. Arrhythmias are caused by disruptions in the electrical signals that regulate the heartbeat, leading to conditions such as atrial fibrillation, ventricular tachycardia, and bradycardia. Therapeutic interventions are tailored to the type and severity of the arrhythmia and may include medications, lifestyle changes, and advanced medical procedures. Medications such as beta-blockers, calcium channel blockers, and antiarrhythmic drugs are often prescribed to control the heart rate and rhythm. For more severe cases, procedures like catheter ablation, which involves destroying the abnormal heart tissue causing the arrhythmia, or the implantation of devices like pacemakers and defibrillators to regulate heartbeats are employed. These treatments not only improve quality of life but also significantly reduce the risk of complications such as stroke and heart failure.

Advancements in cardiac arrhythmias therapeutics have been propelled by ongoing research and technological innovations. The development of more precise and effective ablation techniques, including the use of robotic-assisted systems and advanced imaging technologies, has significantly improved the success rates of these procedures. Innovations in medical device technology have led to the creation of more sophisticated pacemakers and defibrillators that offer enhanced functionality, such as remote monitoring and automatic adjustment based on the patient`s activity level. Additionally, the emergence of novel pharmacological agents targeting specific molecular pathways involved in arrhythmogenesis has opened new avenues for treatment. Clinical trials continue to explore the efficacy and safety of these new therapies, offering hope for more effective management of cardiac arrhythmias with fewer side effects.

The growth in the cardiac arrhythmias therapeutics market is driven by several factors, including the increasing prevalence of cardiovascular diseases due to aging populations, lifestyle changes, and rising rates of conditions such as hypertension and diabetes, which are known risk factors for arrhythmias. Technological advancements in diagnostic tools, such as portable ECG monitors and wearable devices, have enabled earlier and more accurate detection of arrhythmias, facilitating timely intervention. Consumer behavior has also shifted, with patients becoming more proactive about their health and seeking advanced treatment options. Additionally, healthcare providers and payers are increasingly recognizing the long-term cost benefits of early and effective arrhythmia management, leading to better insurance coverage and reimbursement policies for these therapies. The regulatory environment has become more supportive of innovation, with faster approval processes for new drugs and devices. Together, these factors are ensuring robust growth and continuous advancement in the cardiac arrhythmias therapeutics market, ultimately enhancing patient outcomes and reducing the burden of these conditions on healthcare systems worldwide.

Select Competitors (Total 36 Featured) -
  • Abbott Cardiovascular
  • Acesion Pharma ApS
  • Baxter International Inc.
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Covis Pharma
  • Eli Lilly and Company
  • J&J MedTech
  • Mayne Pharma Group Limited
  • Medtronic
  • Novartis Pharma AG
  • Pfizer Inc
  • Roche Diagnostics Corporation
  • Upsher-Smith Laboratories, LLC
  • Viatris Inc.;
Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Cardiac Arrhythmias Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Prevalence of Heart Diseases Globally Drives Demand for Arrhythmia Therapeutics
Advances in Pharmacological Treatments Enhance Management of Cardiac Arrhythmias
Technological Innovations in Cardiac Monitoring and Diagnostic Devices Lead to Increased Disease Identification & Treatment
Growing Awareness of Heart Health and Preventative Care Stimulates Market Growth
Gene- and Cell-Based Therapies Drive Market Growth
Role of Digital Health and Remote Monitoring in Patient Management
Aging Population & Risk of Arrhythmia Represent a Demographic Driver of Growth
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Cardiac Arrhythmias Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 3: World Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 4: World 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Sodium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 6: World Historic Review for Sodium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 7: World 16-Year Perspective for Sodium-Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Beta-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 9: World Historic Review for Beta-Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 10: World 16-Year Perspective for Beta-Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Potassium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 12: World Historic Review for Potassium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 13: World 16-Year Perspective for Potassium-Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Calcium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 15: World Historic Review for Calcium-Channel Blockers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 16: World 16-Year Perspective for Calcium-Channel Blockers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 18: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 19: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 20: USA Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 21: USA Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 22: USA 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
CANADA
TABLE 23: Canada Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 24: Canada Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 25: Canada 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
JAPAN
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 26: Japan Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 27: Japan Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 28: Japan 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
CHINA
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 29: China Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 30: China Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 31: China 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
EUROPE
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 33: Europe Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 34: Europe 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
TABLE 35: Europe Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 36: Europe Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 37: Europe 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
FRANCE
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 39: France Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 40: France 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
GERMANY
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 41: Germany Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 42: Germany Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 43: Germany 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
ITALY
TABLE 44: Italy Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 45: Italy Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 46: Italy 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
UNITED KINGDOM
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 47: UK Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 48: UK Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 49: UK 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
SPAIN
TABLE 50: Spain Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 51: Spain Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 52: Spain 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
RUSSIA
TABLE 53: Russia Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 54: Russia Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 55: Russia 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
REST OF EUROPE
TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 57: Rest of Europe Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 58: Rest of Europe 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
ASIA-PACIFIC
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 60: Asia-Pacific Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 61: Asia-Pacific 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
TABLE 62: Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 63: Asia-Pacific Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 64: Asia-Pacific 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
AUSTRALIA
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
TABLE 65: Australia Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 66: Australia Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 67: Australia 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
INDIA
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
TABLE 68: India Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 69: India Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 70: India 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
SOUTH KOREA
TABLE 71: South Korea Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 72: South Korea Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 73: South Korea 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
REST OF ASIA-PACIFIC
TABLE 74: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 75: Rest of Asia-Pacific Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 76: Rest of Asia-Pacific 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
LATIN AMERICA
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
TABLE 77: Latin America Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 78: Latin America Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 79: Latin America 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
TABLE 80: Latin America Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 81: Latin America Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 82: Latin America 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
ARGENTINA
TABLE 83: Argentina Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 84: Argentina Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 85: Argentina 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
BRAZIL
TABLE 86: Brazil Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 87: Brazil Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 88: Brazil 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
MEXICO
TABLE 89: Mexico Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 90: Mexico Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 91: Mexico 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
REST OF LATIN AMERICA
TABLE 92: Rest of Latin America Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 93: Rest of Latin America Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 94: Rest of Latin America 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
MIDDLE EAST
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
TABLE 95: Middle East Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
TABLE 96: Middle East Historic Review for Cardiac Arrhythmias Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 97: Middle East 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
TABLE 98: Middle East Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 99: Middle East Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 100: Middle East 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
IRAN
TABLE 101: Iran Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 102: Iran Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 103: Iran 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
ISRAEL
TABLE 104: Israel Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 105: Israel Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 106: Israel 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
SAUDI ARABIA
TABLE 107: Saudi Arabia Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 108: Saudi Arabia Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 109: Saudi Arabia 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
UNITED ARAB EMIRATES
TABLE 110: UAE Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 111: UAE Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 112: UAE 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
REST OF MIDDLE EAST
TABLE 113: Rest of Middle East Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 114: Rest of Middle East Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 115: Rest of Middle East 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
AFRICA
Cardiac Arrhythmias Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
TABLE 116: Africa Recent Past, Current & Future Analysis for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
TABLE 117: Africa Historic Review for Cardiac Arrhythmias Therapeutics by Drug Class - Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
TABLE 118: Africa 16-Year Perspective for Cardiac Arrhythmias Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Sodium-Channel Blockers, Beta-Blockers, Potassium-Channel Blockers, Calcium-Channel Blockers and Other Drug Classes for the Years 2014, 2024 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings